PSMA‐Triggered Phase Separation of Peptide‐Drug Conjugates Enables Zinc‐Dependent Tumor Inhibition
Angewandte Chemie International Edition · 09.01.2026 · 65 (2)
DOI: 10.1002/anie.202518980 ↗Kurz gefasst
Fachartikel in der Zeitschrift Angewandte Chemie International Edition, online erschienen am 20.11.2025. Verfasst von Kai Han und 11 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Medical Molecule Science and Pharmaceutics Engineering, Ministry of Industry and Information Technology, Ministry of Industry and I…. Hauptthemen laut MEDLINE: Zinc, Antineoplastic Agents, Peptides, Glutamate Carboxypeptidase II. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Beijing Natural Science Foundation, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Peptide‐drug conjugates (PDC) have emerged as a promising modality for targeted tumor therapy, offering high specificity, and design flexibility. However, the therapeutic efficacy of PDC is often limited by rapid systemic clearance, inadequate control over drug release kinetics, and difficulty in forming stable drug‐tumor interfaces in vivo. These challenges highlight the need for next‐generation PDC systems capable of spatiotemporal regulation and enhanced pharmacological activity. In this study, a structurally adaptive PDC platform termed LE‐HOA was developed based on cascade reconstruction induced by liquid‐liquid phase separation (LLPS). This platform was constructed by covalently linking a tumor‐targeting peptide (LE) ligand with the inhibitor 4‐(hydroxyamino)‐4‐oxobutanoic acid (HOA). LE‐HOA could self‐assemble into nanomicelles under physiological conditions, enhancing drug stability during circulation. Under PSMA induction, HOA was exposed through disassembly, which in turn inhibited the zinc‐dependent enzymatic activity of PSMA. This further induced LLPS, resulting in the rapid formation of nanofiber that expanded drug‐tumor recognition interface. Both in vitro and in vivo studies demonstrated that LE‐HOA enabled sustained pharmacological signaling and effective tumor suppression with good biosafety. These findings suggest a new strategy to address limitations in PDC therapeutics by integrating intelligent response and dynamic phase behavior for enhanced lesion‐targeted action.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Medical Molecule Science and Pharmaceutics Engineering, Ministry of Industry and Information Technology, Ministry of Industry and Information Technology, Key Laboratory of Cluster Science of Ministry o…
- Spallation Neutron Source Science Center, Dongguan, 523803, China.
ORCID-Profile: Weizhi Wang
Förderung
- National Natural Science Foundation of China
- Beijing Natural Science Foundation
- Fundamental Research Funds for the Central Universities
- Natural Science Foundation of Hebei Province
- Natural Science Foundation of Beijing Municipality
Zitieren
APA
Han, K., Zhang, J., Miao, X., Yu, Y., Zhang, L., Zhao, J., Wang, X., Wei, Q., Li, Y., Ke, Y., Ma, B., & Wang, W. (2026). PSMA‐Triggered Phase Separation of Peptide‐Drug Conjugates Enables Zinc‐Dependent Tumor Inhibition. Angewandte Chemie International Edition, 65(2). https://doi.org/10.1002/anie.202518980
Vancouver
Han K, Zhang J, Miao X, Yu Y, Zhang L, Zhao J, et al. PSMA‐Triggered Phase Separation of Peptide‐Drug Conjugates Enables Zinc‐Dependent Tumor Inhibition. Angewandte Chemie International Edition. 2026;65(2). doi:10.1002/anie.202518980
BibTeX
@article{Han2026,
author = {Han, Kai and Zhang, Jian and Miao, Xiaolu and Yu, Yao and Zhang, Limin and Zhao, Jinge and Wang, Xin and Wei, Qinsong and Li, Yongming and Ke, Yubin and Ma, Bing and Wang, Weizhi},
title = {PSMA‐Triggered Phase Separation of Peptide‐Drug Conjugates Enables Zinc‐Dependent Tumor Inhibition},
journal = {Angewandte Chemie International Edition},
year = {2026},
volume = {65},
number = {2},
doi = {10.1002/anie.202518980}
}
EUVIMED